 | Up a level |
Sacks-Davis, Rachel; van Santen, Daniela K; Boyd, Anders; Young, Jim; Stewart, Ashleigh; Doyle, Joseph S; Rauch, Andri; Mugglin, Catrina; Klein, Marina; van der Valk, Marc; Smit, Colette; Jarrin, Inmaculada; Berenguer, Juan; Lacombe, Karine; Requena, Maria-Bernarda; Wittkop, Linda; Leleux, Olivier; Bonnet, Fabrice; Salmon, Dominique; Matthews, Gail V; ... (2024). Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies. The Lancet HIV, 11(2), e106-e116. Elsevier 10.1016/S2352-3018(23)00267-9
Martinello, Marianne; Carson, Joanne M; Van Der Valk, Marc; Rockstroh, Jürgen K; Ingiliz, Patrick; Hellard, Margaret; Nelson, Mark; Lutz, Thomas; Bhagani, Sanjay; Kim, Arthur Y; Hull, Mark; Cordes, Christiane; Moon, Juhi; Feld, Jordan J; Gane, Ed; Rauch, Andri; Bruneau, Julie; Tu, Elise; Applegate, Tanya; Grebely, Jason; ... (2023). Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study. AIDS, 37(12), pp. 1883-1890. Wolters Kluwer Health 10.1097/QAD.0000000000003651
Carson, Joanne M; Barbieri, Sebastiano; Cunningham, Evan; Mao, Eric; van der Valk, Marc; Rockstroh, Jürgen K; Hellard, Margaret; Kim, Arthur; Bhagani, Sanjay; Feld, Jordan J; Gane, Ed; Thurnheer, Maria C; Bruneau, Julie; Tu, Elise; Dore, Gregory J; Matthews, Gail V; Martinello, Marianne (2023). Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study. Journal of the International AIDS Society, 26(9), e26168. BioMed Central 10.1002/jia2.26168
Isfordink, Cas J; Boyd, Anders; Sacks-Davis, Rachel; van Santen, Daniela K; Smit, Colette; Martinello, Marianne; Stoove, Mark; Berenguer, Juan; Wittkop, Linda; Klein, Marina B; Rauch, Andri; Salmon, Dominique; Lacombe, Karine; Stewart, Ashleigh; Schinkel, Janke; Doyle, Joseph S; Hellard, Margaret; van der Valk, Marc; Matthews, Gail V (2023). Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. The lancet. Public health, 8(4), e294-e304. Elsevier 10.1016/S2468-2667(23)00056-7
Matthews, Gail V; Bhagani, Sanjay; Van der Valk, Marc; Rockstroh, Juergen; Feld, Jordan J; Rauch, Andri; Thurnheer, Christine; Bruneau, Julie; Kim, Arthur; Hellard, Margaret; Shaw, David; Gane, Ed; Nelson, Mark; Ingiliz, Patrick; Applegate, Tanya L; Grebely, Jason; Marks, Phillipa; Martinello, Marianne; Petoumenos, Kathy; Dore, Gregory J; ... (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), pp. 829-839. Elsevier 10.1016/j.jhep.2021.04.056
Cunningham, Evan B; Hajarizadeh, Behzad; Amin, Janaki; Litwin, Alain H; Gane, Edward; Cooper, Curtis; Lacombe, Karine; Hellard, Margaret; Read, Phillip; Powis, Jeff; Dalgard, Olav; Bruneau, Julie; Matthews, Gail V; Feld, Jordan J; Dillon, John F; Shaw, David; Bruggmann, Philip; Conway, Brian; Fraser, Chris; Marks, Philippa; ... (2020). Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical infectious diseases, 71(7), e115-e124. Oxford University Press 10.1093/cid/ciz1089
Boettiger, David C; Salazar Vizcaya, Luisa Paola; Dore, Gregory J; Gray, Richard T; Law, Matthew G; Callander, Denton; Lea, Toby; Rauch, Andri; Matthews, Gail V (2020). Can Australia reach the World Health Organization Hepatitis C elimination goal by 2025 among HIV-positive gay and bisexual men? Clinical infectious diseases, 70(1), pp. 106-113. Oxford University Press 10.1093/cid/ciz164
Cunningham, Evan B; Amin, Janaki; Feld, Jordan J; Bruneau, Julie; Dalgard, Olav; Powis, Jeff; Hellard, Margaret; Cooper, Curtis; Read, Phillip; Conway, Brian; Dunlop, Adrian J; Norton, Briana; Litwin, Alain H; Hajarizadeh, Behzad; Thurnheer Zürcher, Maria Christine; Dillon, John F; Weltman, Martin; Shaw, David; Bruggmann, Philip; Gane, Edward; ... (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International journal of drug policy, 62, pp. 14-23. Elsevier 10.1016/j.drugpo.2018.08.013
Sacks-Davis, Rachel; Doyle, Joseph S; Rauch, Andri; Béguelin, Charles Antoine; Pedrana, Alisa E; Matthews, Gail V; Prins, Maria; van der Valk, Marc; Klein, Marina B; Saeed, Sahar; Lacombe, Karine; Chkhartishvili, Nikoloz; Altice, Frederick L; Hellard, Margaret E (2018). Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. Journal of the International AIDS Society, 21 Suppl 2(Suppl 2), e25051. BioMed Central 10.1002/jia2.25051
Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H; Marks, Philippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V; Powis, Jeff; ... (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The lancet. Gastroenterology & hepatology, 3(3), pp. 153-161. Elsevier 10.1016/S2468-1253(17)30404-1
